The Clinical Value of miRNA-21 in Cervical Cancer: A Comprehensive Investigation Based on Microarray Datasets

zhimin Deng
Renmin Hospital of Wuhan University

Chen-Liang Zhou
Renmin Hospital of Wuhan University

Fang-Fang Dai
Renmin Hospital of Wuhan University

Shi-Yi Liu
Renmin Hospital of Wuhan University

Dong-Yong Yang
Renmin Hospital of Wuhan University

Yi-Fan Jia
Renmin Hospital of Wuhan University

Yan-Xiang Cheng (✉️ 2015302180196@whu.edu.cn)
Renmin Hospital of Wuhan University

Research Article

Keywords: miR-21, cervical cancer, EPAS1, HIF-2α, PI3K/AKT/mTOR

Posted Date: December 13th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1131670/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Previous work has demonstrated that the expression of microRNA-21 (miR-21) is implicated in cervical cancer (CC). However, little is known regarding its associations with clinical parameters. We first conducted a meta-analysis using data from Gene Expression Omnibus (GEO) microarrays and The Cancer Genome Atlas (TCGA). Then, enrichment analysis and hub gene screening were performed by bioinformatics methods. Finally, the roles of the screened target genes in CC were explored. From the meta-analysis, more miR-21 was expressed in cancer tissues than in adjacent nontumor tissues ($P < 0.05$). In addition, 46 genes were predicted as potential targets of miR-21. After enrichment analyses, it was detected that these genes were enriched in various cancer pathways, including the phosphatidylinositol signaling system and mammalian target of rapamycin (mTOR) signaling pathway. In this study, bioinformatics tools and meta-analysis validated that miR-21 may function as a highly sensitive and specific marker for the diagnosis of CC, which may provide a novel approach to the diagnosis and treatment of CC.

1. Introduction

Cervical cancer (CC) is one of the most common gynecological carcinomas worldwide, resulting in an unacceptably high mortality rate. Despite continuous advances in the early screening and treatment of CC, its incidence has shown a younger trend in recent years[1]. In addition, the prognoses of patients with CC are still poor. Hence, revealing the molecular characteristics underlying CC and exploring potential therapeutic targets is imperative.

MicroRNAs (miRNAs), a group of small noncoding RNAs, are thought to regulate the expression of a large number of protein-coding genes and are implicated in a variety of biological processes, including the occurrence and development of tumors[2]. MicroRNA-21 (miR-21), an oncogenic microRNA, is involved in angiogenesis, tumor invasion and metastasis and altered in a variety of cancers, such as non-small cell lung cancer and breast cancer[3–5]. In CC, a substantial body of evidence has verified that miR-21 is significantly differentially expressed and regarded as a potential therapeutic target[6–8]. However, little is known regarding its associations with clinical parameters.

Here, we first calculated the expression level of miR-21 in CC based on those data from Gene Expression Omnibus (GEO) microarrays and The Cancer Genome Atlas (TCGA). And then, diagnostic meta-analysis was used to clarify the diagnostic value of miR-21. What's more, bioinformatics analysis, containing Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO), and protein-protein interaction (PPI) network analyses, was operated to mining the underlying mechanisms of miR-21. In a word, meta-analysis and further bioinformatic technique were aimed to exploration of the role of miR-21 in CC.

2. Materials And Methods

2.1 Data collection and the expression level of miR-21
A microarray search in CC was conducted in the GEO database (https://www.ncbi.nlm.nih.gov/geo/). Those datasets without expression of miR-21 were excluded. Next, the expression levels and clinical parameter data for miR-21 were extracted from TCGA (https://cancergenome.nih.gov/). Correlations between the parameters and the miR-21 expression levels were calculated by IBM SPSS 22.0. The number, mean (M) and standard deviation (SD) of the control and experimental group were obtained based on the expression profile information. The results of miR-21 expression in each study were visualized by plotting scatter diagrams in GraphPad Prism 8.

2.2 Comprehensive meta-analysis

Meta-analysis was carried out under the R environment using Meta package. The chi-squared test of $Q$ and the $I^2$ statistic were adopted to assess the potential heterogeneity among the studies. Within groups, comparisons were carried out by t-tests. The ratio of the count data was expressed as a percentage (%) and compared using $\chi^2$ tests. In addition, decided to select the model used in the statistical heterogeneity according to the $I^2$ and $P$ value in forest plots. Generally, the random-effects model was adopted when $I^2 > 50\%$ or $P < 0.05$; otherwise, the fixed-effects model was adopted[9]. To explore the potential sources of heterogeneity, sensitivity analysis was also conducted.

To assess the diagnostic value of miR-21 for CC, the pooled specificity, sensitivity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were computed by meta-Disc software. Furthermore, summary receiver operating characteristic (sROC) curves were also drawn in meta-Disc, whereas the ROC curves of each study were plotted in GraphPad Prism. $P < 0.05$ was considered significant.

2.3 Latent targets of miR-21 in CC and the functional analysis

On the one hand, mRNA targets of miR-21 were predicted by using the online database miRWalk2.0 (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/) [10]. Only those genes projected by more than 6 of the servers were included. One the other hand, the highly expressed genes in CC were downloaded from GEPIA2 (http://gepia2.cancer-pku.cn/) [11]. The intersection of the genes from the two sources were recognized as target genes of miR-21. This procedure was implemented in Vennny 2.1.0 (https://bioinfogp.cnb.csic.es/tools/venny/index.html).

Subsequently, the pathways that the target genes were enriched in were analyzed using R software[12, 13]. The circular plot of the KEGG pathways was plotted by an online platform for data analysis and visualization (http://www.bioinformatics.com.cn). And then, String (http://string-db.org/cgi/input.pl) software was used to construct and visualize the protein-protein interaction (PPI) network between those genes[14]. Based on the PPI network, the hub nodes were investigated by the maximal clique centrality (MCC) algorithm in CytoHubba, a plug-in in Cytoscape[15]. According to the order of the MCC values, the top 4 were defined as hub genes.

2.4 The expression of hub genes and further validation
Given that four genes were identified, their expression boxplots and disease-free survival (DFS) curves were downloaded from GEPIA2 initially. Subsequently, the correlations between miR-21 and the identified hub genes were verified via LinkedOmics (http://www.linkedomics.org/) [16]. Both these two steps were aimed to shrink the scope of genes and further obtain final targets.

We next validated the miR-21 binding site on final targets via miRactDB database on the one hand [17], and GeneCards (http://www.genecards.org/#) were applied to connect the final targets with the interested KEGG enriched pathways on the other hand [18]. In detail, the genes involved in the interested pathways were collected, and then the STRING were performed to constructed the PPI network of the collection of final targets and the pathway genes. In this process, miR-21 and cancer-related pathways were credible linked through the identified final targets.

3. Results

3.1 The expression of miR-21 in CC through GEO microarrays

The workflow of the study is illustrated in Fig. 1A, while Fig. 1B displays the flow chart of the search and selection process. Eventually, 3 microarrays from GEO database (GSE86100 [19], GSE30656 [20], GSE19611 [21]) plus the data download from TCGA, resulted in four studies including 376 cases in total were included in this study. The specific information is displayed in Table 1. In addition, the expression data of miR-21 from the tumor tissues and adjacent noncancerous tissues (serving as control groups) are shown in Fig. 2A-D. The CC groups had a significantly higher level of miR-21 expression than the control groups in GSE86100, GSE30656, and TCGA ($P = 0.0141$, $P < 0.0001$, $P < 0.001$), while no notable distinction was detected in GSE19611 ($P = 1.009$).

| Accession  | GPL     | Year | CESC  | Normal  | Source |
|------------|---------|------|-------|---------|--------|
|            |         |      |       |         |        |
| N          | M       | SD   | N     | M       | SD     |
| GSE86100   | GPL19730| 2016 | 6     | 5.652   | 0.888  | 6      | 1.667 | 3.184 | Tissue |
| GSE30656   | GPL6955 | 2012 | 19    | 12.745  | 0.671  | 10     | 10.845 | 0.911 | Tissue |
| GSE19611   | GPL7534 | 2010 | 4     | 0.312   | 0.297  | 19     | 0.057 | 0.277 | Tissue |
| TCGA       | —       | 2019 | 309   | 18.417  | 0.518  | 3      | 15.761 | 0.659 | Tissue |

3.2 The meta-analysis of the data and the diagnostic value of miR-21
As can be seen from the results of our meta-analysis (Fig. 2E), since the degree of heterogeneity were high ($I^2 = 89\%, \ P < 0.01$), a random-effects model was applied. The combined standardized mean difference (SMD) greater than zero (2.50) were considered as further supporting evidence of the higher expression of miR-21. The sensitivity analysis as defined in Fig. 2F, after omitting GSE30656, the combined SMD became moot (95% CI = -0.12–5.16), which proved that our results were not stable enough.

Next, the diagnostic meta-analysis results signified that the pooled specificity, sensitivity, PLR, NLR and DOR were described in Fig. 3A-E, respectively. It can be seen from Fig. 4A-E, the area under the curve (AUC) either ROC curves or sROC curve were very high, which implied the performance of our model is good. This also elucidated that increased expression of miR-21 in CC has diagnostic value.

Furthermore, the relationship between miR-21 and clinicopathological features were also explored in TCGA database based on the 309 CC samples and the 3 adjacent nontumor tissues. As illustrated in Table 2, miR-21 expression in CC was much higher than that in adjacent noncancerous tissues. In addition, in patients with distant metastasis (M1), it was significantly lower than that in patients without distant metastasis (M0) ($P < 0.05$). Nevertheless, there is no statistical significance between miR-21 expression and other of the analyzed clinical pathological features.
Table 2
Association between miR-21 expression and clinical features from the TCGA dataset.

| Variables                  | Terms                        | N  | Mean ± SD         | p value   |
|----------------------------|------------------------------|----|-------------------|-----------|
| Tissue                     | Adjacent noncancerous tissue | 3  | 15.761±0.657      | < 0.0001* |
|                            | CESC                         | 309| 18.417±0.518      |           |
| Pathological diagnosis     | SCC                          | 257| 18.421±0.529      | 0.6443    |
|                            | ASCA                         | 55 | 18.251±0.765      |           |
| Age(years)                 | < 60                         | 245| 18.331±0.563      | 0.3353    |
|                            | ≥ 60                         | 67 | 18.408±0.584      |           |
| Clinical grade             | I-II                         | 236| 18.391±0.571      | 0.9344    |
|                            | III-IV                       | 69 | 18.397±0.633      |           |
| T stage                    | T1-T2                        | 217| 18.379±0.617      | 0.1239    |
|                            | T3-T4                        | 32 | 18.559±0.617      |           |
| N stage                    | N0                           | 138| 18.352±0.633      | 0.9913    |
|                            | N1-N3                        | 62 | 18.351±0.574      |           |
| M stage                    | M0                           | 116| 18.408±0.528      | 0.0022*   |
|                            | M1                           | 11 | 17.851±0.892      |           |
| Race                       | White                        | 214| 18.371±0.566      | 0.6409    |
|                            | Nonwhite                     | 62 | 18.331±0.672      |           |

Note: CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; SCC, squamous cell carcinoma; ASCA, adenocarcinoma; SD, standard deviation; T stage, size or direct extent of the primary tumor; N stage, degree of spread to regional lymph nodes; M stage, presence of distant metastasis. *p < 0.05 was considered statistically significant.

3.3 Identifying promising miR-21 target genes in CC using bioinformatics

A total of 169 genes were obtained by more than six algorithms from miRWALK2.0, while 5758 overexpressed genes were collected from GEPIA2. After intersection, 46 predicted target genes were selected (Fig. 5A and Table S1).

To further discover the function of miR-21 in CC, KEGG and GO annotations were performed. Details were provided in Fig. 5B-D, Table S2 and Table S3. Of note, the KEGG enrichment analysis revealed that miR-21 can make a critical difference in CC through multiple pathways, including the phosphatidylinositol signaling system and mammalian target of rapamycin (mTOR) signaling pathway (Fig. 5C and Fig. 5D).
Fig. 5E displayed the PPI network diagrams. What's more, the top 4 hub genes (MAF, EPAS1, PIKFYVE, and SACM1 L) were calculated via Cytoscape.

3.4 The expression and prognosis of miR-21 target genes

Subsequently, the correlations between miR-21 and the identified hub genes were verified via LinkedOmics (http://www.linkedomics.org/)

The expression level of the four hub genes obtained in the previous step and their DFS curves are shown in Fig. 6A-D. From the figure, we found all four genes were significantly downregulated in the CC group compared to the control group. Notably, only EPAS1 expression was related to prognosis ($P = 0.041$), while the remaining 3 hub genes were not associated with an improved DFS (MAF: $P = 0.35$, PIKFYVE: $P = 0.24$, SACM1 L: $P = 0.12$). The correlation of the identified target genes with miR-21 in CC is shown in Fig. 7A-D. Similarly, there were only EPAS1 hold a weak positive correlation ($r = 0.1657$) with miR-21, which was statistically significant. Given this, EPAS1 were regarded as the final target of miR-21 and used in following analyses.

According to previous GO enrichment analysis, those candidate targets are enriched in DNA-binding transcription activator activity and phosphatidylinositol phosphate phosphatase activity, both of which are associated with oncology. The KEGG analysis results revealed that mi-21 may involve in the phosphatidylinositol and the mTOR signaling pathways. One of the most prestigious phosphatidylinositol pathways is the phosphatidyl-inositol 3-kinase/serine-threonine kinase (PI3K/AKT) signaling pathway, which is implicated in the development and progression of cancers. Therefore, PI3K/AKT/mTOR was considered as a candidate signaling pathway.

In the process of validation, Table 3 illustrated that there were miR-21 binding sites both on the promotor and coding region of EPAS1 were predicted by miRactDB. Moreover, a total of 31 genes, including 30 genes within the PI3K/AKT/mTOR signaling pathway downloaded from the PathCards module of GeneCards database and the EPAS1 gene, were applied to constructed PPI network. In Fig. 7E, it's clearly apparent that EPAS1, the final target of miR-21, were strongly interlinked with the PI3K/AKT/mTOR signaling pathway. Along this process, miR-21 and the cancer-involved pathways were contacted via EPAS1.

| Gene  | miRNA | Start | End  | seed seq. with additional 2bp | miRNA seed seq. |
|-------|-------|-------|------|-------------------------------|-----------------|
| miRNA binding site in promoter region of gene of plus strand (TSS +/- 2kb regions) |
| EPAS1 | miR-21| 1090  | 1096 | UGGGUUGUUAAUU                | AACACCA         |
| miRNA binding site in coding region (CDS) |
| EPAS1 | miR-21| 1055  | 1061 | CGUGGUUGUUCU                | AACACCA         |
Discussion

A growing body of evidence has suggested that miR-21 plays a fundamental role in migration, invasion, metastasis, and proliferation of breast cancer, head and neck squamous cell carcinoma, gastric cancer, colorectal cancer, etc.[22–26]. In this study, when exploring the association of miR-21 with clinicopathological parameters, it was related to the tissue type (adjacent noncancerous tissue or CC samples) and the occurrence of distant tumor metastasis (M0 or M1). This also indicate that miR-21 may be involved in the occurrence and development of CC.

Studies have examined that it may be a suitable diagnostic biomarker for colorectal cancer, with moderate sensitivity and specificity[27], and it has good diagnostic value in breast cancer and colorectal cancer[28, 29]. However, the potential diagnostic value of miR-21 in CC and its correlations with clinical features has seldom been studied. The present study focused on investigating the role and latent mechanism of miR-21 in CC by co-applying meta-analysis and bioinformatics approach.

Here, increased expression of miR-21 was found in GSE86100, GSE30656 and TCGA, but in GSE19611, no significant differences were observed. A possible reason for this may be the limited number of tumor samples. Only 4 tumor samples of the 23 samples in GSE19611. Furthermore, a meaningless combined SMD emerged when a sensitivity analysis was conducted (Fig. 2F). We can see from Fig. 2E, although the sample size of GSE30656 was not the largest, its weighting ratio was the highest, reaching 25.7%. Given this, once GSE30656 was removed, the analysis results severely fluctuated. In the future, higher quality and larger sample size studies need to be performed for analysis to obtain more instructive conclusions.

From Fig. 2E, forest plot of the meta-analysis, the combined SMD was 2.50 (95% CI: 0.72 - 4.27, random-effects model). Additionally, the AUC either ROC curves or sROC curve were all > 0.7 (Fig. 4A-E). In a word, our meta-analysis results demonstrated that miR-21 has potential as a highly sensitive and specific biomarker in CC. Subsequently, we performed a series of bioinformatics assay.

On the one hand, PI3K/AKT/mTOR was thought a candidate signaling pathway after the enrichment analysis. Of note, many research suggesting that it could be used as a novel biomarker for the assessment of risk of developing CC[30–32]. Some other miRNAs have been proven to inhibit the activity of human CC cells by inhibiting this pathway, such as miRNA-99b[33] and miRNA-383[34]. What's more, the effect of miR-21 on PI3K/AKT/mTOR pathway has also been demonstrated in other diseases. Based on the above information, it can be reasonably speculated that miR-21 may affect the invasion and migration of CC cells by regulating the PI3K/AKT/mTOR pathway. This may be a potential mechanism by which miR-21 promotes CC development and progression.

On the other hand, EPAS1 were screened to be the final target of miR-21. EPAS1 is the only one that has a statistically significant correlation with DFS and it has the largest Spearman correlation coefficients with miR-21 among the four candidate target genes. The miR-21 binding sites on it were also identified. Endothelial PAS domain protein 1 (EPAS1), which is also known as hypoxia-inducible factor-2α (HIF-2α), belongs to the family of hypoxia-inducible factors (HIFs)[35]. Hypoxia is a common feature of many solid
tumors, including CC. The mTOR pathway, which is essential for cell proliferation, is repressed under hypoxia. As early as 2012, reports showed that activation of the HIF-2α pathway increases mammalian target of rapamycin complex 1 (mTORC1) activity[36]. Moreover, a recent paper reported that HIF-2α could promote the apoptosis of breast cancer cells via the PI3K/AKT/mTOR signaling pathway[37]. Although the function of EPAS1 in the tumorigenesis of CC is yet clear, we have demonstrated that EPAS1 were tightly linked with the PI3K/AKT/mTOR pathway. Thus, we speculated that EPAS1 plays an important role in CC through the PI3K/AKT/mTOR pathway.

It is undeniable that this study has several limitations. First, the composition of the samples differed somewhat due to the differences in data sources. For example, in the TCGA database, there were 309 cases of CC tissues and 3 cases of adjacent nontumor tissues (Table 2 and Fig. 2D), while the corresponding figures in the GEPIA2 database were 306 and 13, respectively (Fig. 6). There is a risk that a mistake will occur, but not to the extent to which it could influence the reliability of the data, as TCGA databases with large data volumes are included. Next, because only four independent datasets were incorporated, we did not assess the risk of publication bias. Finally, due to the HPV infection status in TCGA are unavailable, we failed to identify the relationship of HPV-related CC and miR-21 expression.

Taken together, the results of this study confirm that miR-21 is upregulated and plays a vital role in the occurrence and development of CC. More importantly, miR-21 has the potential to be a novel, highly sensitive, highly specific, noninvasive biomarker for the diagnosis of CC, but additional large-scale studies are required to verify its diagnostic value. The results of bioinformatics research present a new method for exploring the pathogenesis of CC and will guide our experimental thinking.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article.

**Availability of data and materials**

The datasets generated and/or analyzed during the current study are available in the GEO repository (https://www.ncbi.nlm.nih.gov/geo/) and TCGA datasets (https://portal.gdc.cancer.gov/legacy-archive/search/f).

**Competing interests**
The authors declare that they have no competing interests.

**Funding**

This work was supported by the Key Research and Development Program of Hubei Province under Grant number 2020BCB023. And the funders took part in the study design of this manuscript.

**Authors' contributions**

FFD and CLZ collected and initially screened the data. SYL and DYY screened the data again and collected information about the patients. YFJ and YXC guided the research ideas of the full text. ZMD performed a visual analysis of the data and was the main contributor to the manuscript. All authors read and approved the final manuscript.

**Acknowledgments**

This work was supported by the Key Research and Development Program of Hubei Province under Grant number 2020BCB023. And the funders took part in the study design of this manuscript.

**References**

1. Vu M, Yu J, Awolude OA, Chuang L: *Cervical cancer worldwide*. *Curr Probl Cancer* 2018, 42(5):457–465.

2. Cai L, Wang W, Li X, Dong T, Zhang Q, Zhu B, Zhao H, Wu S: MicroRNA-21-5p induces the metastatic phenotype of human cervical carcinoma cells by targeting the von Hippel-Lindau tumor suppressor. *Oncol Lett* 2018, 15(4):5213–5219.

3. Del Mar Díaz-González S, Rodríguez-Aguilar ED, Meneses-Acosta A, Valadez-Graham V, Deas J, Gómez-Cerón C, Tavira-Montalván CA, Arizmendi-Heras A, Ramírez-Bello J, Zurita-Ortega ME et al: Transregulation of microRNA miR-21 promoter by AP-1 transcription factor in cervical cancer cells. *Cancer Cell Int* 2019, 19:214.

4. Bica-Pop C, Cojocneanu-Petric R, Magdo L, Raduly L, Gulei D, Berindan-Neagoe I: Overview upon miR-21 in lung cancer: focus on NSCLC. *Cell Mol Life Sci* 2018, 75(19):3539–3551.

5. Petrović N: miR-21 Might be Involved in Breast Cancer Promotion and Invasion Rather than in Initial Events of Breast Cancer Development. *Mol Diagn Ther* 2016, 20(2).

6. Zhang L, Zhan X, Yan D, Wang Z: Circulating MicroRNA-21 Is Involved in Lymph Node Metastasis in Cervical Cancer by Targeting RASA1. *Int J Gynecol Cancer* 2016, 26(5):810–816.

7. Liu L, Wang Y-L, Wang J-F: [Differential expression of miR-21, miR-126, miR-143, miR-373 in normal cervical tissue, cervical cancer tissue and Hela cell]. *Sichuan Da Xue Xue Bao Yi Xue Ban* 2012, 43(4):536–539.

8. Yao T, Lin Z: MiR-21 is involved in cervical squamous cell tumorigenesis and regulates CCL20. *Biochim Biophys Acta* 2012, 1822(2):248–260.
9. Li J, Liu K, Zhang T, Yang Z, Wang R, Chen G, Kang M: A comprehensive investigation using meta-analysis and bioinformatics on miR-34a-5p expression and its potential role in head and neck squamous cell carcinoma. *Am J Transl Res* 2018, 10(8):2246–2263.

10. Dweep H, Gretz N: *miRWalk2.0: a comprehensive atlas of microRNA-target interactions*. *Nat Methods* 2015, 12(8):697.

11. Tang Z, Kang B, Li C, Chen T, Zhang Z: *GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis*. *Nucleic Acids Res* 2019, 47(W1):W556-W560.

12. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT et al: *Gene ontology: tool for the unification of biology*. The Gene Ontology Consortium. *Nat Genet* 2000, 25(1):25–29.

13. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M: *KEGG for integration and interpretation of large-scale molecular data sets*. *Nucleic Acids Res* 2012, 40(Database issue):D109-D114.

14. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP et al: *STRING v10: protein-protein interaction networks, integrated over the tree of life*. *Nucleic Acids Res* 2015, 43(Database issue):D447-452.

15. Chin C-H, Chen S-H, Wu H-H, Ho C-W, Ko M-T, Lin C-Y: *cytoHubba: identifying hub objects and sub-networks from complex interactome*. *BMC Syst Biol* 2014, 8 Suppl 4:S11.

16. Vasaikar SV, Straub P, Wang J, Zhang B: *LinkedOmics: analyzing multi-omics data within and across 32 cancer types*. *Nucleic Acids Res* 2018, 46(D1):D956-D963.

17. Tan H, Kim P, Sun P, Zhou X: *miRactDB characterizes miRNA-gene relation switch between normal and cancer tissues across pan-cancer*. *Brief Bioinform* 2021, 22(3).

18. Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, Nativ N, Bahir I, Doniger T, Krug H et al: *GeneCards Version 3: the human gene integrator*. *Database (Oxford)* 2010, 2010:baq020.

19. Gao D, Zhang Y, Zhu M, Liu S, Wang X: *miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China*. *PLoS ONE* 2016, 11(10):e0164701.

20. Wilting SM, Snijders PJ, Verlaat W, Jaspers A, van de Wiel MA, van Wieringen WN, Meijer GA, Kenter GG, Yi Y, Le Sage C et al: *Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis*. *Oncogene* 2013, 32(1):106–116.

21. Pereira PM, Marques JP, Soares AR, Carreto L, Santos MA: *MicroRNA expression variability in human cervical tissues*. *PLoS ONE* 2010, 5(7):e11780.

22. Masoudi MS, Mehrarian E, Mirzaei H: *MiR-21: A key player in glioblastoma pathogenesis*. *J Cell Biochem* 2018, 119(2):1285–1290.

23. Irimie-Aghiorghiesei AI, Pop-Bica C, Pintea S, Braicu C, Cojocneanu R, Zimţa A-A, Gulei D, Slabî O, Berindan-Neagoe I: *Prognostic Value of MiR-21: An Updated Meta-Analysis in Head and Neck Squamous Cell Carcinoma (HNSCC)*. *J Clin Med* 2019, 8(12).

24. Li P-F, Chen S-C, Xia T, Jiang X-M, Shao Y-F, Xiao B-X, Guo J-M: *Non-coding RNAs and gastric cancer*. *World J Gastroenterol* 2014, 20(18):5411–5419.
25. Nedaenia R, Avan A, Ahmadian M, Nia SN, Ranjbar M, Sharifi M, Goli M, Piroozmand A, Nourmohammadi E, Manian M et al: Current Status and Perspectives Regarding LNA-Anti-miR Oligonucleotides and microRNA miR-21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer. J Cell Biochem 2017, 118(12):4129–4140.

26. Pardini B, De Maria D, Francavilla A, Di Gaetano C, Ronco G, Naccarati A: MicroRNAs as markers of progression in cervical cancer: a systematic review. BMC Cancer 2018, 18(1):696.

27. Shan L, Ji Q, Cheng G, Xia J, Liu D, Wu C, Zhu B, Ding Y: Diagnostic value of circulating miR-21 for colorectal cancer: a meta-analysis. Cancer Biomark 2015, 15(1):47-56.

28. Jinling W, Sijing S, Jie Z, Guinian W: Prognostic value of circulating microRNA-21 for breast cancer: a systematic review and meta-analysis. Artif Cells Nanomed Biotechnol 2017, 45(6):1–6.

29. Moridikia A, Mirzaei H, Sahebkar A, Salimian J: MicroRNAs: Potential candidates for diagnosis and treatment of colorectal cancer. J Cell Physiol 2018, 233(2):901–913.

30. Xu J, Zhu W, Chen L, Liu L: MicroRNA–433 inhibits cell growth and induces apoptosis in human cervical cancer through PI3K/AKT signaling by targeting FAK. Oncol Rep 2018, 40(6):3469–3478.

31. Haddadi N, Lin Y, Travis G, Simpson AM, Nassif NT, McGowan EM: PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy. Mol Cancer 2018, 17(1):37.

32. Bahrami A, Hasanzadeh M, Hassanian SM, ShahidSales S, Ghayour-Mobarhan M, Ferns GA, Avan A: The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy. J Cell Biochem 2017, 118(12):4163–4169.

33. Li YJ, Wang Y, Wang YY: MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway. J Cell Physiol 2019, 234(6):9577–9591.

34. Teng P, Jiao Y, Hao M, Tang X: microRNA-383 suppresses the PI3K-AKT-MTOR signaling pathway to inhibit development of cervical cancer via down-regulating PARP2. J Cell Biochem 2018, 119(7):5243–5252.

35. Albadari N, Deng S, Li W: The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy. Expert Opin Drug Discov 2019, 14(7):667–682.

36. Elorza A, Soro-Arnáiz I, Meléndez-Rodríguez F, Rodríguez-Vaello V, Marsboom G, de Cárcer G, Acosta-Iborra B, Albacete-Albacete L, Ordóñez A, Serrano-Oviedo L et al: HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5. Mol Cell 2012, 48(5):681–691.

37. Bai J, Chen W-B, Zhang X-Y, Kang X-N, Jin L-J, Zhang H, Wang Z-Y: HIF-2α regulates CD44 to promote cancer stem cell activation in triple-negative breast cancer PI3K/AKT/mTOR signaling. World J Stem Cells 2020, 12(1):87–99.

Figures
Figure 1

(A) The flow diagram of this study. (B) Flow chart of the literature screening process and results. Note: miR-21, microRNA-21; GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas; GEPIA, Gene Expression Profiling Interactive Analysis; DFS, disease-free survival; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; PPI, protein-protein interaction network.
Figure 2

(A-D) Scatterplot of the miR-21 expression levels in the included cervical cancer studies. (A) GSE86100; (B) GSE30656; (C) GSE19611; (D) TCGA. (E) A forest plot of miR-21 expression between CC and adjacent nontumor tissues. (F) Sensitivity analysis of the selected four studies. Note: Normal, adjacent nontumor tissues; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; TCGA, The Cancer Genome Atlas.
Figure 3

Forest plots described the diagnosis value of miR-21 of cervical cancer. (A) Sensitivity; (B) Specificity; (C) Positive likelihood ratio; (D) Negative likelihood ratio; (E) Diagnostic odds ratio.
Figure 4

(A-D) Receiver operating characteristic (ROC) curves based on 4 studies. (A) GSE86100; (B) GSE30656; (C) GSE19611; (D) TCGA. (E) Summary receiver operating characteristic (sROC) curve for the diagnostic value of miR-21 in cervical cancer.
Figure 5

(A) The intersection of GEPIA2 and miRWalk2.0 to obtain predictive target genes. (B) Gene ontology terms categorization and distribution of the miR-21 targeted genes. (C) Chord plot of the KEGG pathways. (D) Bar graph of the KEGG pathways. (E) The PPI networks of the target genes of miR-21.
Figure 6

Expression level and disease-free survival curves of hub genes in CC samples and normal tissues. (A) SACM1 L; (B) PIKFYVE; (C) MAF; (D) EPAS1. Notes: Expression of the hub genes was detected in 306 cervical cancer tissues (T) and 13 adjacent nontumor tissues (N) on the basis of the GEPIA database, with the cutoff criteria of $|\log_{2}FC| \geq 1.0$ and adj. p < 0.05. SACM1 L, suppressor of actin mutations 1-like; PIKFYVE, phosphoinositide kinase, FYVE-type zinc finger containing; MAF, macrophage activating factor; EPAS1, endothelial PAS domain protein 1.
Figure 7

(A-D) Spearman's analysis was used to show the correlations between the miR-21 expression levels and the validated target genes. (A) SACM1 L; (B) PIKFYVE; (C) MAF; (D) EPAS1. (E) The PPI network between EPAS1 and genes within the PI3K/AKT/mTOR signaling pathway. Notes: SACM1 L, suppressor of actin mutations 1-like; PIKFYVE, phosphoinositide kinase, FYVE-type zinc finger containing; MAF, macrophage activating factor; EPAS1, endothelial PAS domain protein 1.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementarytable.docx